MannKind Corp
Company Profile
Business description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Contact
1 Casper Street
DanburyCT06810
USAT: +1 818 661-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
592
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.60 | 16.00 | -0.18% |
| CAC 40 | 8,382.43 | 15.58 | 0.19% |
| DAX 40 | 24,999.53 | 147.50 | -0.59% |
| Dow JONES (US) | 52,627.90 | 119.63 | 0.23% |
| FTSE 100 | 10,515.92 | 13.47 | -0.13% |
| HKSE | 24,681.10 | 340.37 | 1.40% |
| NASDAQ | 26,238.49 | 131.48 | 0.50% |
| Nikkei 225 | 68,751.51 | 1,008.01 | 1.49% |
| NZX 50 Index | 13,635.07 | 16.15 | -0.12% |
| S&P 500 | 7,564.52 | 20.93 | 0.28% |
| S&P/ASX 200 | 8,841.10 | 15.90 | -0.18% |
| SSE Composite Index | 3,955.58 | 11.55 | -0.29% |